MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p.

doi:10.1093/hmg/3.10.1841

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p.

Human molecular genetics - 1 Oct 1994

Ueki K, Rubio M P, Ramesh V, Correa K M, Rutter J L, von Deimling A, Buckler A J, Gusella J F, Louis D N

Abstract excerpt

Human astrocytomas frequently have allelic losses of chromosome 9p, suggesting the presence of a 9p astrocytoma tumor suppressor gene. The MTS1 (or CDKN2) gene on chromosome 9p encodes a cell-cycle regulator and is deleted in approximately 80% of astrocytoma cell lines. To determine whether MTS1 is the tumor suppressor gene involved in human astrocytoma formation in vivo, we have analyzed chromosome 9p allelic...

Topics

Alleles
Astrocytoma
Base Sequence
Carrier Proteins
Chromosome Deletion
Chromosome Mapping
Chromosomes, Human, Pair 9
Cyclin-Dependent Kinase Inhibitor p16
DNA Primers
Exons
Genes, Tumor Suppressor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Genetic Markers

Humans

Molecular Sequence Data

Polymerase Chain Reaction

Polymorphism, Genetic

Polymorphism, Restriction Fragment Length

Reference Values

Source

Open in PubMed

Identifiers

PMID: 7849711
DOI: 10.1093/hmg/3.10.1841

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-7849711-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p.PMID 7849711Read ↗

CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.Semantic proximity Read ↗

Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma.Semantic proximity Read ↗

Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomasSemantic proximity Read ↗

Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter.Semantic proximity Read ↗

TP53 gene mutations and 17p deletions in human astrocytomas.Semantic proximity Read ↗

Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade.Semantic proximity Read ↗

A common region of homozygous deletion in malignant human gliomas lies between the IFN alpha/omega gene cluster and the D9S171 locus.Semantic proximity Read ↗

p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma.Semantic proximity Read ↗

Absence of mutation of the p73 gene in astrocytic neoplasms.Semantic proximity Read ↗

Homozygous Deletions of the <i>CDKN2C</i>/p 18<sup>INK4C</sup> Gene on the Short Arm of Chromosome 1 in Anaplastic OligodendrogliomasSemantic proximity Read ↗

Allelotype of human malignant astrocytoma.Semantic proximity Read ↗

The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesotheliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.